January 6, 2020   Is deep learning the future of diabetic retinopathy screening? Deep learning could have an application in the diagnosis and management of retinal diseases. Here’s what clinicians need to know. Learn more   Research targets gene therapy for exudative AMD patients Two anti-VEGF gene therapies are being investigated in clinical trials of patients with exudative age-related macular degeneration. Initial efficacy and safety results are encouraging. Learn more   Tracking anti-VEGF use among Medicare Part B beneficiaries Anti-VEGF agents have ushered in a new era of treatment for retinal and choroidal neovascularization. Here’s what researchers have learned in determining how these agents have evolved over time, specifically regarding trends for U.S. Medicare Part B beneficiaries. Find out       RELATED ARTICLES How the use of anti-VEGF agents is evolving over time Myopia may prove beneficial in preventing DR development Guidelines for treating the diabetic eye patient What AAO attendees learned from a single session devoted to diabetes